Sign inJoin waitlistJoin the waitlist

CP

Crystal Proud

Clinical Assistant Professor · Old Dominion University

Credentials: · · · · ·

History

Old Dominion University
Present
Old Dominion University
Present

Neuromuscular Medicine
Stanford Health Care
2014–2015
Child Neurology
Stanford Health Care
2013–2014
Pediatrics
Emory University School of Medicine
2009–2011
Eastern Virginia Medical School
2005–2009

Research

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial
Nature Medicine · 2025 · 143 citations
Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)
Annals of Neurology · 2023 · 86 citations
Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry
Journal of Neuromuscular Diseases · 2024 · 63 citations

Aravindhan Veerapandiyan
9 papers · 1 as a fellow
Craig McDonald
9 papers
Craig Zaidman
8 papers
Jerry Mendell
7 papers
Perry Shieh
5 papers
Richard Finkel
5 papers
Susan Matesanz
5 papers
Anne Connolly
4 papers
Diana Bharucha-Goebel
4 papers
Emma Ciafaloni
4 papers
Julie Parsons
4 papers
Russell Butterfield
4 papers

Clinical trials

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Site PI · Recruiting · Phase 3
Biogen
2026–2032
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
Site PI · Recruiting · Phase 3
Biogen
2026–2032
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
Site PI · Recruiting · Phase 2
argenx
2025–2029
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
Site PI · Recruiting · Phase 3
Biogen
2025–2029